MX2019008276A - Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados. - Google Patents

Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados.

Info

Publication number
MX2019008276A
MX2019008276A MX2019008276A MX2019008276A MX2019008276A MX 2019008276 A MX2019008276 A MX 2019008276A MX 2019008276 A MX2019008276 A MX 2019008276A MX 2019008276 A MX2019008276 A MX 2019008276A MX 2019008276 A MX2019008276 A MX 2019008276A
Authority
MX
Mexico
Prior art keywords
tlr
toll
conjugates
receptor
arm polymer
Prior art date
Application number
MX2019008276A
Other languages
English (en)
Inventor
Cai Haiying
Miyazaki Takahiro
Ren Zhongxu
K Anand Neel
Liang DENG Bo-
V Joshi Bhalchandra
Zalevsky Jonathan
KIVIMAE Saul
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2019008276A publication Critical patent/MX2019008276A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan conjugados polimericos multibrazo de agonistas del receptor de tipo Toll ("TLR"), tales como agonistas de TLR 7/8, asi como composiciones relacionadas, y metodos para preparar y usar dichos conjugados. Los conjugados ejemplares estan abarcados por la Formula I: (ver formula) o una forma de sal farmaceuticamente aceptable de los mismos, donde R, tomado junto con cada Q, es un residuo de un poliol, politiol o poliamina que tiene de 3 a aproximadamente 50 grupos hidroxilo, tiol o amino; cada Q es un conector seleccionado de oxigeno, azufre y -NH; cada POLI es independientemente un polimero soluble en agua, no peptidico; cada Xr es independientemente un resto espaciador que contiene un conector; q es un numero entero positivo de 3 a aproximadamente 50; y cada TLR 7/8 AG es un agonista del receptor 7/8 de tipo Toll. Tambien se proporciona un metodo para administrar a un paciente que tiene cancer (a) una cantidad activadora de IL-2Rß de un agonista selectivo de IL-2Rß de accion prolongada; y (b) un agonista del receptor de tipo Toll tal como un conjugado, como se describe anteriormente, asi como composiciones, kits y métodos relacionados.
MX2019008276A 2017-01-10 2018-01-10 Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados. MX2019008276A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762444756P 2017-01-10 2017-01-10
US201762444735P 2017-01-10 2017-01-10
US201762467945P 2017-03-07 2017-03-07
US201762488407P 2017-04-21 2017-04-21
US201762488251P 2017-04-21 2017-04-21
US201762510019P 2017-05-23 2017-05-23
US201762510024P 2017-05-23 2017-05-23
PCT/US2018/013199 WO2018132496A1 (en) 2017-01-10 2018-01-10 Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods

Publications (1)

Publication Number Publication Date
MX2019008276A true MX2019008276A (es) 2019-09-16

Family

ID=61231306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008276A MX2019008276A (es) 2017-01-10 2018-01-10 Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados.

Country Status (10)

Country Link
US (2) US11744898B2 (es)
EP (1) EP3568162A1 (es)
JP (2) JP7250679B2 (es)
KR (1) KR102619747B1 (es)
CN (1) CN110167598A (es)
AU (1) AU2018207283C1 (es)
CA (1) CA3049254A1 (es)
IL (2) IL297655A (es)
MX (1) MX2019008276A (es)
WO (1) WO2018132496A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
EP3628010A4 (en) * 2017-05-02 2021-02-17 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
AU2018316694A1 (en) 2017-08-17 2020-02-13 Nektar Therapeutics Immunotherapeutic tumor treatment method
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
CA3125488A1 (en) * 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2021202923A1 (en) 2020-04-02 2021-10-07 Nektar Therapeutics Immunomodulator for the prevention and treatment of coronovirus infection and other conditions
CA3176356A1 (en) 2020-04-22 2021-10-28 Anne BROOKS Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202208617A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
US20230293685A1 (en) 2020-05-04 2023-09-21 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
TW202242085A (zh) 2020-12-31 2022-11-01 美商艾歐凡斯生物治療公司 供自動生產腫瘤浸潤淋巴球的裝置和方法
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
TW202300014A (zh) 2021-03-05 2023-01-01 美商艾歐凡斯生物治療公司 腫瘤儲存及細胞培養組成物
CA3212439A1 (en) 2021-03-19 2022-09-22 Michelle SIMPSON-ABELSON Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CA3219148A1 (en) 2021-05-17 2022-11-24 Frederick G. Vogt Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
EP4377446A1 (en) 2021-07-28 2024-06-05 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AU2022343729A1 (en) 2021-09-09 2024-03-21 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
TW202331735A (zh) 2021-10-27 2023-08-01 美商艾歐凡斯生物治療公司 協調用於患者特異性免疫療法之細胞之製造的系統及方法
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023220608A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
PT1719511E (pt) 2001-11-16 2009-03-06 Coley Pharm Group Inc N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
US20050079155A1 (en) 2003-03-20 2005-04-14 Xencor, Inc. Generating protein pro-drugs using reversible PPG linkages
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101242858B (zh) 2005-06-16 2012-12-19 尼克塔治疗公司 具有可降解键的轭合物以及用于制备这种轭合物的聚合物试剂
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
US8637466B2 (en) * 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
EA028288B1 (ru) 2009-05-27 2017-10-31 Селекта Байосайенсиз, Инк. Наноносители, имеющие компоненты с различными скоростями высвобождения
CN102711837B (zh) 2009-11-18 2016-10-19 尼克塔治疗公司 盐形式的多-臂聚合物-药物偶联物
IL295201A (en) * 2010-11-12 2022-10-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
MX347240B (es) 2011-06-03 2017-04-20 3M Innovative Properties Co Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
JP2015504881A (ja) * 2011-12-20 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 胃腸感染および障害を処置するための医薬組成物および方法
US9556167B2 (en) * 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
US10010587B2 (en) 2014-02-21 2018-07-03 Nektar Therapeutics IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Also Published As

Publication number Publication date
US11744898B2 (en) 2023-09-05
CA3049254A1 (en) 2018-07-19
JP2023071870A (ja) 2023-05-23
AU2018207283C1 (en) 2024-05-02
IL297655A (en) 2022-12-01
US20210128737A1 (en) 2021-05-06
IL267929B (en) 2022-11-01
AU2018207283A2 (en) 2019-07-25
AU2018207283B2 (en) 2024-02-15
IL267929A (en) 2019-09-26
JP2020514300A (ja) 2020-05-21
KR102619747B1 (ko) 2023-12-29
US20230372500A1 (en) 2023-11-23
KR20190104377A (ko) 2019-09-09
JP7250679B2 (ja) 2023-04-03
IL267929B2 (en) 2023-03-01
EP3568162A1 (en) 2019-11-20
CN110167598A (zh) 2019-08-23
AU2018207283A1 (en) 2019-07-18
WO2018132496A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2019008276A (es) Conjugados de polimero multibrazo de compuestos agonistas de tlr y metodos de tratamiento inmunoterapeutico relacionados.
MX2021015221A (es) Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
MX2022003740A (es) Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
PH12021551159A1 (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CY1110925T1 (el) Νεες ενωσεις
CL2022003648A1 (es) Conjugados de una molécula de unión celular con análogos de camptotecina
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
MX2009011005A (es) Sellador polimerico para tejido.
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
WO2007092646A3 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CY1113339T1 (el) Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες
GB201101665D0 (en) Immunogenic compositions
WO2005113012A3 (en) Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
MX368966B (es) Conjugados de proteina-polimero-farmaco.
MX2022004875A (es) Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
MX2012001654A (es) Metodos para usar moduladores de c-met.
AR060187A1 (es) Composicion inmunogenica
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
WO2008076270A3 (en) Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
GB0701366D0 (en) Novel pharmaceutical compositions
MX2020009149A (es) Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos.